TP53 and B-cell chronic lymphocytic leukemia: Up to now, the only clinical evidence of the impact of RP genetic changes on chemotherapy resistance based on a reduced activation of the RP-MDM2-p53 pathway comes from the study by Ljungström et al. [118] on the relationship between RPS15 mutations and clinical outcome of patients with chronic lymphocytic leukemia.